PMH33 Health insurance cost of parkinson disease in Hungary: A cost of illness study  by Oberfrank, F. et al.
 V A L U E  I N  H E A L T H  1 6  ( 2 0 1 3 )  A 1 - A 2 9 8  A61 
 
 
MEPS employs a complex, probabilistic survey design, standard error estimates 
were computed using the ‘SURVEY’ procedures of SAS. RESULTS: The percentage 
of the total US population on ADHD medications grew from 0.7% in 2000 to 1.4% 
in 2010 with an estimated average annual utilization growth rate of 13.1%. 
Aggregate spending on all ADHD medications increased from $684.9 million in 
2000 to $3.6 billion in 2010 with an estimated average annual spending growth 
rate of 42.7%. Average spending on ADHD medication per user increased from 
$356.9 (SE=$23.0) in 2000 to $816.2 (SE=$55.5) in 2010. Stimulants accounted for 
over 70% of total yearly spending on all ADHD medications between 2000 and 
2010. From 2002, long-acting stimulants accounted for the majority (>60%) of the 
total yearly spending on stimulant medications. Furthermore, across the years 
by demographic sub-groups, younger children (≤12 years), males, individuals on 
private health insurance, and low/middle income families had the highest ADHD 
utilization rates (>37%) and accounted for the highest proportion (>39%) of 
spending on all ADHD medications. CONCLUSIONS: A steady growth in ADHD 
medication use and expenditure was observed across 2000 to 2010 with the key 
growth drivers being younger children (≤12 years), males, individuals on private 
health insurance, and low/middle income families.  
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OBJECTIVES: To calculate the annual health insurance treatment cost of 
Parkinson disease in Hungary. METHODS: The data derive from the financial 
database of the Hungarian National Health Insurance Fund Administration 
(NHIFA), the only health care financing agency in Hungary. We analyzed the 
health insurance treatment cost and the number of patients for the year 2010. 
The following cost categories were included into the study: out-patient care, in-
patient care, CT-MRI, PET, home care, transportation, general practitioner, drugs 
and medical devices. RESULTS: The Hungarian National Health Insurance Fund 
Administration spent 5.349 billion Hungarian Forint (HUF) (EUR 19.16 million) for 
the treatment of Parkinson patients. The annual average expenditure per patient 
was HUF 45897 (EUR 164) while the average expenditure per one inhabitant was 
HUF 534 (EUR 1.9). Major cost drivers were pharmaceuticals (77.4% of total health 
insurance costs), general practitioners (9.6%) and out-patient care (7.1%). The 
number of Parkinson patients was 116 per 100000 populations. We found the 
highest patient number in pharmaceutical budget (116545 patients), out-patient 
care (74562 patients) and general practitioners (59993 patients). CONCLUSIONS: 
Parkinson disease represents a significant burden for the health insurance 
system. Pharmaceutical treatment is the major cost driver for Parkinson disease.  
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OBJECTIVES: To evaluate treatment patterns, dosage and drug costs of extended-
release injectable paliperidone palmitate among schizophrenia patients. 
METHODS: Patients (≥18 years) with at least 1 inpatient or 2 outpatient visits on 
separate dates with a primary or secondary diagnosis of ICD-9-CM code 295.X 
before initiating paliperidone palmitate (index event) were identified from the 
MarketScan® Research database (7/1/2008-9/30/2011). Patients were required to 
have 12 months of continuous insurance coverage before the index event. The 
follow-up period was variable and patients were followed till insurance 
disenrollment or end of study period, whichever occurred first. RESULTS: Among 
1,578 Medicaid insured schizophrenia patients who initiated paliperidone 
palmitate, mean age was 39 years, 56% were male, 44% were Caucasian, and 49% 
were African American. Prior to initiating paliperidone palmitate, 49% of patients 
had previously used other extended-release antipsychotics injectables, of which 
the most frequently used were risperidone (28%) and haloperidol (17%); 84% 
patients had used non-extended-release antipsychotics, of which the most 
frequently used were risperidone (38%), quetiapine (27%), and paliperidone (26%). 
Mean dosage of the first paliperidone palmitate injection was 193mg with 
maintenance doses ranging between 157 and 172 mg over the follow-up period. 
The mean number of days between injections ranged 31-33 days. The mean cost 
of first paliperidone palmitate injection was $1,329 with maintenance injections 
ranging between $1,079 and $1,212. Treatment patterns and drug costs were 
similar for commercially insured schizophrenia patients identified from the 
same database. CONCLUSIONS: This is one of the first studies that evaluates the 
dosage and costs of a 2nd generation extended-release injectable used in clinical 
practice. Among patients who initiated paliperidone palmitate, approximately 
half used at least one other extended-release injectable prior to paliperidone 
initiation and higher ranges of available doses of paliperidone palmitate were 
being utilized during maintenance therapy.  
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OBJECTIVES: To estimate the costs to pharmacy and health care services, cost-
benefit and cost-effectiveness of extending methadone maintenance treatment 
(MMT) and buprenorphine-naloxone maintenance treatment (BNMT) of a 
Scottish community sample of opioid-dependent individuals from eight to 
sixteen months. METHODS: Structured face-to-face interviews were conducted 
with 71 opioid-dependent individuals at study intake and then again after six 
and fourteen months of maintenance treatment with either methadone or 
buprenorphine-naloxone to obtain data on their utilisation of pharmacy and 
health care services between interviews. The main outcome measures were the 
marginal cost-benefit ratio (MCBR) associated with extending MMT and BNMT 
from eight to sixteen months and the incremental cost-effectiveness ratio 
(MCER) in terms of cost per additional heroin-free day gained by extending MMT 
and BNMT from eight to sixteen months. Sensitivity analyses were conducted to 
estimate the probability that extending each maintenance treatment from eight 
to sixteen months would be cost-saving and lead to gains in heroin-free days 
compared to only eight months of maintenance treatment. RESULTS: 
Bootstrapping analysis based on 10,000 data resamples indicated that extending 
BNMT from eight to sixteen months had a 61% chance of being cost-beneficial to 
the NHS. By contrast, extending MMT had only a 13% chance of being cost-
beneficial. A bootstrapping analysis of 10,000 pairs of costs and effects (heroin-
free days gained) indicated that extending BNMT was cost-effective (negative 
costs and positive effects) for 79% of simulated patients; extending MMT was 
cost-effective for 21% of simulated patients. Acceptability curves showed that 
decision-makers could be 95% and 81% confident that investing £40 would 
achieve an additional heroin-free day in buprenorphine-naloxone patients and 
methadone patients, respectively. CONCLUSIONS: Extending BNMT from eight to 
sixteen months was estimated to be significantly more likely than extended 
MMT to be cost-beneficial and cost-effective to the NHS in the long-term 
outpatient treatment of opioid-dependence.  
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OBJECTIVES: According to WHO, depression is a disease entity that generates 
affective disorders and causes severe impact on patient mood, which affects 
almost 121 million people worldwide. The aim of this analysis is to evaluate the 
cost-effectiveness of desvenlafaxine in major depressive disorder in the 
Colombian population from the institutional perspective. METHODS: A Markov 
model simulates the clinical course of a hypothetical cohort of patients >18 years 
with major depressive disorder. Patients may have up to three depressive 
episodes along the ten-state model developed through eight-week cycles, using a 
timeframe of five years and 3% annual discount rate. Comparators were: 
desvenlafaxine (50 mg/day), fluoxetine (20 mg/day), paroxetine (20 mg/day), 
duloxetine (60 mg/day) and escitalopram (20 mg/day). Effectiveness measures 
and adverse events were taken from a literature review, utilities and costs were 
taken from a local health institution (“Clínica Nuestra Señora de la Paz”), costs 
are expressed in 2012 USD. Effectiveness measures were depression-free weeks, 
days lost due to absenteeism, QALYs, and outcome was incremental cost-
effectiveness ratio. RESULTS: Over a 5-year period, desvenlafaxine obtained 
3.5129 QALYs, fluoxetine 3.4950; paroxetine 3.4896; duloxetina 3.4961, and 
escitalopram 3.4971. Total expected costs were for desvenlafaxine US$3640.30, 
fluoxetine US$3642.90; paroxetine US$3537.60, duloxetine US$3949.50 and 
escitalopram US$3275.30. Depression-free weeks were higher with 
desvenlafaxine (79.91) and lower with paroxetine (76.83); days lost due to 
absenteeism were lower with desvenlafaxine (69.19) and higher with paroxetine 
(383.28). CONCLUSIONS: For the treatment of major depressive disorder, 
desvenlafaxine is a cost-effective alternative compared to paroxetine 
(ICER=US$4,409.60/QALY) and escitalopram (ICER=US$23,104.50/QALY); 
desvenlafaxine is a cost-saving alternative compared to fluoxetina and 
duloxetina with a higher number of QALYs and lower costs.  
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OBJECTIVES: To estimate the cost-effectiveness of atypical antipsychotics as 
treatment for patients with manic episodes in the bipolar disorder structure 
during one year. METHODS: A literature-based cost-effectiveness analysis was 
developed to estimate the costs of bipolar disorder patients initiating therapy 
with quetiapine, aripiprazole, olanzapine, risperidone or ziprasidone. Direct 
expenses associated with bipolar disorder and resulting follow-up costs were 
calculated using general tariff agreement of Russian obligatory insurance system 
and official national statistics. For reference, accepted exchange rate was 1 EUR = 
40 RUB. RESULTS: Compared to quetiapine or risperidone, aripiprazole, 
olanzapine or ziprasidone results in increases in drug therapy costs: 133,464 RUB 
(3,337 EUR) in quetiapine group, 127,462 RUB (3,187 EUR) in risperidone group, 
334,766 RUB (8,369 EUR) in aripiprazole group, 186,457 RUB (4,661 EUR) in 
olanzapine group and 197,108 RUB (4,928 EUR) in ziprasidone group per patient. 
The values of cost/remission for one year are estimated at 87,806 RUB (2,195 EUR) 
in quetiapine group, 72,012 RUB (1 800 EUR) in risperidone group, 187,020 RUB 
(4,676 EUR) in aripiprazole group, 111 651 RUB (2,791 EUR) in olanzapine group 
and 153,990 RUB (3,850 EUR) in ziprasidone group per patient. CONCLUSIONS: 
